Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pediatric Cancers Clear all
Recruiting Not applicable Interventional

Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy

NCT06096272
View directory record Official record
Conditions
Cerebral Palsy, Mobile Phone Use, Pediatric ALL, Physical Disability, Physical Inactivity
Interventions
Augment Reality Exergames
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
5 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 1 Interventional

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

NCT05429502
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Temozolomide, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting Phase 2 Interventional

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

NCT05253495
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 39 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Study of How Proton Beam Radiotherapy (PBRT) Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor

NCT05288439
View directory record Official record
Conditions
Brain Tumor, Metastatic Brain Tumor
Interventions
Resting-state functional connectivity MRI, Neurocognitive battery with quality-of-life assessment
Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Not applicable Interventional

Reduction of Environmental Tobacco Smoke (ETS) Exposure In Pediatric Cancer Patients

NCT00766766
View directory record Official record
Conditions
Cancer
Interventions
Health Risk and Behavioral Skills Coaching Sessions, Telephone Coaching Sessions, Physician Feedback Letter
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 17 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia

NCT00462787
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, clofarabine, dexamethasone, thiotepa, topotecan hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 28 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prehospital Provider Training With Augmented Reality (AR)

NCT05686590
View directory record Official record
Conditions
Hypoglycemia, Pediatric ALL
Interventions
Augmented Reality Headset
Behavioral
Lead sponsor
Thomas Caruso
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Mountain View, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial

NCT00939380
View directory record Official record
Conditions
Childhood Cancers
Interventions
Behavioral intervention sessions, CD-ROM, DVD and pamphlet, Respite care
Behavioral · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting Phase 1 Interventional

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

NCT07297979
View directory record Official record
Conditions
Ewing Sarcoma
Interventions
Xaluritamig
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Not applicable Interventional Results available

Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects

NCT01864291
View directory record Official record
Conditions
Bilateral Hearing Loss for Causes Other Than Tumors
Interventions
Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Months to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 1 Interventional Results available

Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

NCT03198234
View directory record Official record
Conditions
AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Mixed Phenotype Acute Leukemia, NHL - Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, ALL
Interventions
T-allo10
Biological
Lead sponsor
Roncarolo, Maria Grazia, MD
Other
Eligibility
3 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting Phase 2 Interventional

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

NCT06541847
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
HLX-1502
Drug
Lead sponsor
Healx Limited
Industry
Eligibility
12 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting No phase listed Observational

Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients

NCT02530658
View directory record Official record
Conditions
Solid, Liquid, Central Nervous System Tumors
Interventions
Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, Return of Results Follow-Up Visits, Blood Sample, Skin Biopsy
Other · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2038
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 4 Interventional

A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT

NCT03176849
View directory record Official record
Conditions
Vitamin D Deficiency, Stem Cell Transplant Complications, Pediatric Cancer, Blood Disorder, Pediatric Acute Myeloid Leukemia, Pediatric Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Sickle Cell Anemia in Children, Aplastic Anemia, Thalassemia in Children
Interventions
Vitamin D3, Standard Vitamin D3 Supplementation
Dietary Supplement
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 21, 2026, 6:08 PM EDT
Active, not recruiting Phase 3 Interventional

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795
View directory record Official record
Conditions
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Interventions
Tovorafenib, Chemotherapeutic Agent
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
Up to 25 Years
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

NCT00186953
View directory record Official record
Conditions
Abdominal Neoplasms, Pelvic Neoplasms
Interventions
Optison
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 20 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated No phase listed Observational

Genetic Study of Brain Tumors in Young Children

NCT00010101
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric
Interventions
Not listed
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 3 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Jul 21, 2026, 6:08 PM EDT
Completed No phase listed Observational

Pediatric Oncology Recovery Trial After Surgery

NCT04344899
View directory record Official record
Conditions
Pelvic Cancer
Interventions
Observational
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Month to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Cincinnati, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

NCT03696355
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
GDC-0084, radiation therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 21, 2026, 6:08 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

NCT00582816
View directory record Official record
Conditions
Leukemia, Solid Tumors
Interventions
Clinimacs Cell Separation System, conditioning chemotherapy, DLI
Device · Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Months to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jul 21, 2026, 6:08 PM EDT
Completed No phase listed Observational

Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment

NCT01180881
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Neoplasms
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 25 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

NCT04796012
View directory record Official record
Conditions
Solid Tumor, Rhabdomyosarcoma
Interventions
Atezolizumab, Vincristine, Irinotecan, Temozolomide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Months to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Chicago, Illinois • Boston, Massachusetts • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

NCT04925479
View directory record Official record
Conditions
Myeloid Leukemia, Philadelphia Positive
Interventions
Asciminib Pediatric formulation group, Asciminib Adult formulation group
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

NCT04833582
View directory record Official record
Conditions
Osteosarcoma
Interventions
Azenosertib, Gemcitabine
Drug
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 21, 2026, 6:08 PM EDT